150 related articles for article (PubMed ID: 25501579)
1. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.
van der Sluis TC; van Duikeren S; Huppelschoten S; Jordanova ES; Beyranvand Nejad E; Sloots A; Boon L; Smit VT; Welters MJ; Ossendorp F; van de Water B; Arens R; van der Burg SH; Melief CJ
Clin Cancer Res; 2015 Feb; 21(4):781-94. PubMed ID: 25501579
[TBL] [Abstract][Full Text] [Related]
2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
[TBL] [Abstract][Full Text] [Related]
4. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
5. Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma.
Goh AR; Shin SP; Jung NR; Ryu CH; Eom HS; Lee JH; Choi K; Lee SJ; Jung YS
Cancer Lett; 2015 Jan; 356(2 Pt B):743-50. PubMed ID: 25449436
[TBL] [Abstract][Full Text] [Related]
6. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.
Welters MJ; van der Sluis TC; van Meir H; Loof NM; van Ham VJ; van Duikeren S; Santegoets SJ; Arens R; de Kam ML; Cohen AF; van Poelgeest MI; Kenter GG; Kroep JR; Burggraaf J; Melief CJ; van der Burg SH
Sci Transl Med; 2016 Apr; 8(334):334ra52. PubMed ID: 27075626
[TBL] [Abstract][Full Text] [Related]
7. Delayed vaccine-induced CD8
van der Sluis TC; van Haften FJ; van Duikeren S; Pardieck IN; de Graaf JF; Vleeshouwers W; van der Maaden K; Melief CJM; van der Burg SH; Arens R
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030302
[TBL] [Abstract][Full Text] [Related]
8. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice.
Hoffmann C; Stanke J; Kaufmann AM; Loddenkemper C; Schneider A; Cichon G
J Immunother; 2010; 33(2):136-45. PubMed ID: 20145549
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
10. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.
Berraondo P; Nouzé C; Préville X; Ladant D; Leclerc C
Cancer Res; 2007 Sep; 67(18):8847-55. PubMed ID: 17875726
[TBL] [Abstract][Full Text] [Related]
11. Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.
Beyranvand Nejad E; van der Sluis TC; van Duikeren S; Yagita H; Janssen GM; van Veelen PA; Melief CJ; van der Burg SH; Arens R
Cancer Res; 2016 Oct; 76(20):6017-6029. PubMed ID: 27569212
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression.
van der Sluis TC; Sluijter M; van Duikeren S; West BL; Melief CJ; Arens R; van der Burg SH; van Hall T
Cancer Immunol Res; 2015 Sep; 3(9):1042-51. PubMed ID: 25888578
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
14. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity.
Song YC; Cheng HY; Leng CH; Chiang SK; Lin CW; Chong P; Huang MH; Liu SJ
J Control Release; 2014 Jan; 173():158-65. PubMed ID: 24177312
[TBL] [Abstract][Full Text] [Related]
15. CD40 Accelerates the Antigen-Specific Stem-Like Memory CD8
Zhang Y; Wang N; Ding M; Yang Y; Wang Z; Huang L; Zhu W; Mellor AL; Hou X; Zhou C; Yan R; Wang W; Wu S
Front Immunol; 2020; 11():1012. PubMed ID: 32536922
[TBL] [Abstract][Full Text] [Related]
16. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
Piersma SJ; Jordanova ES; van Poelgeest MI; Kwappenberg KM; van der Hulst JM; Drijfhout JW; Melief CJ; Kenter GG; Fleuren GJ; Offringa R; van der Burg SH
Cancer Res; 2007 Jan; 67(1):354-61. PubMed ID: 17210718
[TBL] [Abstract][Full Text] [Related]
17. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.
Kanodia S; Da Silva DM; Karamanukyan T; Bogaert L; Fu YX; Kast WM
Cancer Res; 2010 May; 70(10):3955-64. PubMed ID: 20460520
[TBL] [Abstract][Full Text] [Related]
18. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
van Meir H; Kenter GG; Burggraaf J; Kroep JR; Welters MJ; Melief CJ; van der Burg SH; van Poelgeest MI
Anticancer Agents Med Chem; 2014 Feb; 14(2):190-203. PubMed ID: 24237223
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.
Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y
Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963
[TBL] [Abstract][Full Text] [Related]
20. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
